Treats partial-onset or primary generalized tonic-clonic seizures. ANDA 216683, held by Rubicon Research. Topiramate.
As of Nov 15, 2026, ANDA 216683 (Topiramate), held by Rubicon Research, was first approved by FDA on May 27, 2025, with 0 approved supplements and 0 published complete response letters.
Topiramate capsules is indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox- Gastaut syndrome in patients 2 years of age and older Preventive treatment of migraine in patients 12 years of age and older 1.1 Monotherapy Epilepsy Topiramate capsules are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 27, 2025 | Original application | Approved | None posted |
| Topiramate15MG · capsule;oral | Topiramate | Rx |
| Topiramate25MG · capsule;oral | Topiramate | Rx |
| Topiramate50MG · capsule;oral | Topiramate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters